This trial is looking at the feasibility of conducting a larger clinical trial to see if neoadjuvant chemotherapy can help improve survival for people with UTUC.
- Bladder Cancer
3 Primary · 3 Secondary · Reporting Duration: 36 months
2 Treatment Groups
Adjuvant Chemotherapy Arm (Standard of Care)
1 of 2
Neoadjuvant Chemotherapy Arm
1 of 2
14 Total Participants · 2 Treatment Groups
Primary Treatment: Gemcitabine · No Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Has the FDA given Gemcitabine the green light?
"Gemcitabine's safety is based on Phase 3 trial data, which suggests that the drug is efficacious and has undergone multiple rounds of safety testing." - Anonymous Online Contributor
What conditions does Gemcitabine typically help?
"Commonly, advanced endometrial cancer is treated with Gemcitabine. However, this chemotherapy drug can also be effective for treating melanoma, lymphoma, non-hodgkin, and advanced sarcoma." - Anonymous Online Contributor
Are you still looking for new test subjects for this clinical trial?
"Yes, as of 4/12/2022 this study is still recruiting patients, according to the listing on clinicaltrials.gov. This particular trial was first advertised on 2/8/2021." - Anonymous Online Contributor